Avacta gets MHRA green-light to start phase I trial for ‘pro…
Avacta Group has receive approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to begin a Phase I trial of a pro-drug form of the chemotherapy doxorubicin. The study will investigate Avacta’s AVA6000, a pro-drug form of the chemotherapy doxorubicin which has been modified using the company’s pre|CISION chemistry. AVA6000 […]
